BiotechTube

ABBV-101

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hematologic Cancer

Conditions

Hematologic Cancer

Trial Timeline

Jun 9, 2023 → Mar 1, 2031

NCT ID
NCT05753501

About ABBV-101

ABBV-101 is a phase 1 stage product being developed by AbbVie for Hematologic Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05753501. Target conditions include Hematologic Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT06887010Phase 1Completed
NCT05753501Phase 1Recruiting

Competing Products

20 competing products in Hematologic Cancer

See all competitors
ProductCompanyStageHype Score
120 mg LY2784544Eli LillyPhase 2
52
RLYB116 for InjectionRallybioPhase 1
25
DS3790a + Combination drug + Combination drugDaiichi SankyoPhase 1/2
41
IsavuconazoleAstellas PharmaPhase 2
52
isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oralAstellas PharmaPhase 1
33
DSP-5336 + [14C]-DSP-5336Sumitomo PharmaPhase 1
33
BBI608 + Dexamethasone + Bortezomib + Imatinib + IbrutinibSumitomo PharmaPhase 1
33
Venetoclax + ethinyl estradiol/levonorgestrelAbbViePhase 1
33
ABT-888 + TemozolomideAbbViePhase 1
33
elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injectionAbbViePhase 2
52
Capivasertib + RabeprazoleAstraZenecaPhase 1
33
AZD9829 + AZD9829AstraZenecaPhase 1/2
41
ridaforolimusMerckPhase 2
52
Pembrolizumab/vibostolimab coformulationMerckPhase 2
52
NemtabrutinibMerckPhase 1
33
Ondansetron + AprepitantMerckPhase 2
52
NemtabrutinibMerckPhase 2
52
ARQ 621MerckPhase 1
33
NemtabrutinibMerckPhase 1
33
PelabresibNovartisPhase 3
77

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85